libre de droit Shares of Shattuck Labs ( NASDAQ: STTK ) traded higher premarket Friday after the company announced updated interim data from an early-stage trial for its lead candidate SL-172154 in combination with chemotherapy azacitidine in blood cancer. The data readout from the company’s Phase 1B dose expansion clinical trial represented previously untreated patients with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) and those with acute myeloid leukemia (AML) and mutations in the TP53 gene. Citing a June 4 data cut for TP53m AML patients, the Austin, Texas-based biotech said SL-172154 with azacitidine led to a 43% objective response rate and a 33% complete remission with incomplete hematologic recovery.
33% of patients witnessed Grade 3 or 4 adverse events, and there were three deaths due to adverse events unrelated to SL-172154. As disclosed in December, an investigator reported Grade 5 cardiac arrest potentially related to the experimental therapy, an argument Shattuck ( STTK ) disputes. Based on an April 23 readout, the company reported a 67% objective response rate for patients with HR-MDS, mainly in those with TP53 mutations.
The initial complete remission/marrow complete remission stood at 58%. “This update shows that the rate of complete remission has improved since our last data release in December, with additional patients in both cohorts who continue to improve on therapy.” Shattuck ( STTK ) CEO Taylor Schreiber.
“These are indications with h.
